Kinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice

Background Kinins are important mediators of inflammation and act through stimulation of two receptor subtypes, B1 and B2. Leukocyte infiltration contributes to the pathogenesis of autoimmune inflammation in the central nervous system (CNS), occurring not only in multiple sclerosis (MS) but also in experimental autoimmune encephalomyelitis (EAE). We have previously shown that the chemokines CCL2 and CCL5 play an important role in the adhesion of leukocytes to the brain microcirculation in EAE. The aim of the present study was to evaluate the relevance of B2 receptors to leukocyte-endothelium interactions in the cerebral microcirculation, and its participation in CNS inflammation in the experimental model of myelin-oligodendrocyte-glycoprotein (MOG)35–55-induced EAE in mice. Methods In order to evaluate the role of B2 receptor in the cerebral microvasculature we used wild-type (WT) and kinin B2 receptor knockout (B2-/-) mice subjected to MOG35–55-induced EAE. Intravital microscopy was used to investigate leukocyte recruitment on pial matter vessels in B2-/- and WT EAE mice. Histological documentation of inflammatory infiltrates in brain and spinal cords was correlated with intravital findings. The expression of CCL5 and CCL2 in cerebral tissue was assessed by ELISA. Results Clinical parameters of disease were reduced in B2-/- mice in comparison to wild type EAE mice. At day 14 after EAE induction, there was a significant decrease in the number of adherent leukocytes, a reduction of cerebral CCL5 and CCL2 expressions, and smaller inflammatory and degenerative changes in B2-/- mice when compared to WT. Conclusion Our results suggest that B2 receptors have two major effects in the control of EAE severity: (i) B2 regulates the expression of chemokines, including CCL2 and CCL5, and (ii) B2 modulates leukocyte recruitment and inflammatory lesions in the CNS.


Background
Bradykinin (BK) and its biologically active metabolites are the functional components of the kallikrein-kinin system. Kinins elicit a wide range of physiological effects including relaxation of vascular smooth muscle in arteries and arterioles, expression of adhesion molecules, leukocyte infiltration, formation of interendothelial gaps and protein extravasation from post-capillary venules, and pain transmission mechanisms [1,2]. The actions of kinins are mediated through stimulation of two subtypes of seventransmembrane-domain G-protein-coupled receptors, namely B 1 and B 2 . The B 2 receptor is constitutively expressed in various cell types, including endothelial cells, nerve fibers, leukocytes and mast cells [3,4]. The B 1 receptor is generally expressed at low levels under normal conditions but is up-regulated by cytokines in stressful situations, such as shock and inflammation [5][6][7]. Most of the physiological actions of kinins are believed to be mediated by stimulation of B2 receptors [8].
Experimental autoimmune encephalomyelitis (EAE) is an inflammatory disease of the CNS mediated by CD4+ Th1 cells that serves as experimental model of human multiple sclerosis (MS). A pathological hallmark of MS is infiltration of immune cells across the blood-brain barrier into the CNS causing myelin destruction and axonal injury [9]. It is thought that inappropriate leukocyte recruitment and activation in the brain results in disease symptoms and progression [10]. Thus, reduction of the migration of immune cells into the CNS is a relevant novel therapeutic strategy for the treatment of MS.
Although the potential role of the kinin system on leukocyte entry into the CNS in MS remains unclear, it has been shown that BK can interfere with the mechanism of leukocyte recruitment in various tissues [11]. BK may enhance the expression of adhesion molecules on endothelium cells [12]. BK antagonists reduce leukocyte-endothelium interactions after diverse inflammatory conditions, including global cerebral ischemia [4], leukocyte infiltration in murine mesenteric post-capillary venules [13] and lung inflammation in guinea pigs [14]. BK could potentially modify leukocyte recruitment by production of chemoattractant molecules, such as chemokines. For example, treatment with bradykinin receptor antagonists has been shown to reduce production of chemokines, including KC and MCP-1, after intestinal ischemia and reperfusion [15]. Several studies, have clearly demonstrated the relevance of chemokines for the recruitment of leukocytes into the brain of EAE mice [16][17][18].
Cross talk between cytokines and kinin receptors has been extensively investigated over the last several years [19][20][21]. Studies have demonstrated that pro-inflammatory cytokines regulate B 1 and B 2 receptor expression [11,22,23] and, conversely, blockade of kinins receptors modifies expression of cytokines and chemokines [24,25]. In the present work, we used B 2 -deficient mice to assess the potential contribution of kinin receptors for the clinical course of disease, leukocyte recruitment, and modulation of chemokines expression in the CNS after EAE induction by MOG  .

Animals
Mice B 2 knockout (B 2 -/-) mice were generated as previously described [24]. Knockout female C57BL/6 X sv129 mice (9-11 wks) and their wild-type (WT) littermate controls were housed under standard conditions and had free access to commercial chow and water. All procedures described in this study had prior approval from the local Ethics Committee that governs animal care and use in research.

EAE induction
B 2 -/and WT mice were immunized subcutaneously at the base of the tail with an emulsion containing 100 μg MOG 35-55 peptide (MEVGWYRSPFSRVVHLYRNGK; (Dept Biophysics, Escola Paulista de Medicina, SP, Brazil) in Freund's complete adjuvant (CFA, Sigma) supplemented with 4 mg/mL Mycobacterium tuberculosis H37RA (Difco Laboratories). Pertussis toxin (Sigma), was injected (300 ng/animal, i.p.), on the day of immunization and 48 h later. Animals were monitored daily and neurological impairment was quantified on an arbitrary clinical scale and presented as mean clinical disease severity. Scores were: 0 = no clinical signs, 1 = tail paralysis (or loss of tail tone), 2 = tail paralysis and hind-limb weakness, 3 = hindlimb paralysis, 4 = complete hind-limb paralysis and front limb weakness [26]. The mice were weighed pre-and 14 days post-immunization, the peak of the disease [18]. "Sham animals" refers to WT animals without EAE induction.

Intravital microscopy in mouse brain
Intravital microscopy of cerebral microvasculature was performed as previously described [18,27]. Briefly, the mice were anaesthetized by intraperitoneal injection of a mixture containing ketamine (150 mg/kg) and xylazine (10 mg/kg). The tail vein was cannulated for administration of fluorescent dyes. A craniotomy was performed using a high-speed drill (Dremel, USA) and the dura matter was removed to expose the underlying pial vasculature. Throughout the experiment, the mouse was maintained at 37°C with a heating pad (Fine Science Tools Inc., Canada) and the exposed brain was continuously superfused with artificial cerebrospinal fluid buffer at pH 7.4, containing in mmol/L: NaCl 132, KCl 2.95, CaCl 2 1.71, MgCl 2 0.64, NaHCO 3 24.6, dextrose 3.71 and urea 6.7, at 37°C.
To assess leukocyte-endothelium interactions, leukocytes were fluorescently labeled by administration of rhodamine 6G (i.v., 0.5 mg/kg body weight) and observed using a microscope (Olympus B201, X20 objective lens, corresponding a 100 μm of area) outfitted with a fluorescent light source (epi-illumination at 510-560 nm, using a 590 nm emission filter). A silicon-intensified camera (Optronics Engineering DEI-470) mounted on the microscope projected the image onto a monitor (Olympus). Rolling leukocytes were defined as the number of white cells moving at a velocity lesser than that of erythrocytes cells. Leukocytes were considered adherent to the venular endothelium if they remained stationary for 30 seconds or longer.

Histopathology
Brains, cerebellum and the spinal cords were removed just after intravital microscopy. Transverse slices of brain, spinal cord and cerebellum were fixed by immersion in 10% formalin and processed for paraffin embedding. The sections (6.0 μm) were stained with H&E and examined in an Olympus BX51 microscope. Documentation was performed by a coupled digital camera and imaging capture software (Megacybernetics Pro-Express version 4.1 and cool-snap kit).

Measurement of chemokines
Brain tissue extracts were obtained from control and EAE mice (WT and B 2 -/-). Brains were removed after intravital microscopy, and the left and right hemispheres were stored on ice. Thereafter, using Ultra-Turrax, each hemisphere was homogenized in extraction solution (100 mg of tissue per 1 mL) containing 0.4 M NaCl, 0.05% Tween 20, 0.5% BSA, 0.1 mM phenylmetilsulfonil fluoride, 0.1 mM benzetonio chloride, 10 mM EDTA and 20 KIU aprotinin. The brain homogenate was spun at 10000 × g for 10 min at 4°C and the supernatants were stored at -70°C. The concentrations of CCL2, CCL3, CCL5, TNFα and IFNγ were determined in the supernatants of the brain extracts, at a 1:3 dilution in PBS containing 1% BSA, using an ELISA set-up commercially available according to the procedure supplied by the manufacturer (R&D Systems, Minneapolis, MN and Pharmingen, San Diego, CA).

Statistical analysis
Data are shown as mean ± SEM. Significance was assessed using an ANOVA parametric test with Bonferroni correction for multiple comparisons. Statistical significance was set at P < 0.05.

Clinical assessment and histopathology
All WT and B 2 -/mice developed EAE after MOG  administration. Clinical symptoms appeared on day 11 post MOG-injection and peaked around day 14 after which were stable through day 18, the last day for animal evaluation. There were no deaths during the course of EAE development. However, B 2 -/mice showed a modest but statistically significant reduction (n = 7, mean clinical severity score = 2.4 ± 0.6) in neurological impairment at the peak of disease (day 14) and during the final plateau phase of disease when compared with their WT group counterparts (n = 7, mean clinical severity score = 3.6 ± 0.24) ( Figure 1A). In addition, there was significant weight loss in EAE WT animals compared to the EAE B 2 -/group ( Figure 1B).
Histopathological evaluation of the brain, cerebellum and spinal cord was performed in WT and B 2 -/mice at day 14 after EAE induction. Brains of EAE WT mice showed a marked perivascular infiltration of mononuclear cells around pial and cerebral cortex venules ( Figure 2A). The inflammatory process extended from the meninges into cerebral cortex parenchyma and was characterized by Clinical assessment of EAE Figure 1 Clinical assessment of EAE. Clinical signs (n = 7 mice/ group) were daily monitored, comparing B 2 -/-(▼) and WT (■) mice during 18 days after EAE induction (A) and body weight gain or loss (B). Data is expressed as mean ± SEM. *P < 0.05 for B 2 -/versus WT on the peak of disease (day 14 post-induction). focal intense mononuclear infiltration. The meninges and white matter of spinal cord of the EAE WT group presented an intense focal inflammatory response associated with white matter vacuolization ( Figure 2C). However, the EAE B 2 -/group showed only discrete focal inflammatory infiltrates of mononuclear cells, predominantly in association with discrete white matter vacuolization (Figure 2B and 2D).

Rolling and adhesion of leukocytes in cerebral microvasculature on day 14
EAE pathogenesis requires migration of activated T cells from peripheral lymphoid tissue to the CNS, which presumably occurs in a multi-step manner. To migrate into sites of inflammation, leukocytes must first tether and roll along the vessel before they firmly adhere and emigrate out of the vasculature. Firm adhesion is triggered by the action of chemoattractant molecules, such as chemokines [26]. EAE induced an increase in leukocyte rolling which presented the same profile in all groups. The deletion of B 2 genes did not alter the rolling of leukocytes on pial vessel walls when compared to WT group ( Figure 3A). EAE also induced an increase of leukocyte adhesion in WT mice ( Figure 3B). On the other hand, leukocyte adhesion was diminished in B 2 -/in comparison with WT mice (Figure 3B). In summary, both leukocyte recruitment and histopathological alterations decreased in B 2 -/when compared to the EAE WT.

Chemokine release in the brain
In order to assess the involvement of kinin receptors in the cerebral chemokine release after EAE induction, brain tis- sues from WT and B 2 -/were examined. EAE induction enhanced cerebral production of the chemokines CCL2 and CCL5 in WT mice ( Figure 4A, B). In B 2 -/mice, the levels of CCL2 were significantly lower than those found in WT mice ( Figure 4A). In addition, the production of CCL5 was lower in B 2 -/mice when compared to their WT controls subjected to EAE ( Figure 4B). There was no difference in cerebral CCL3 expression in WT mice before or after EAE induction ( Figure 4C). Moreover, expression of CCL3 was similar in WT and gene-deficient mice subjected to EAE ( Figure 4C).
Considering the important participation of IFNγ and TNFα in T-cell trafficking to CNS, we evaluated the role of kinin receptors on the cerebral production of these pro-inflammatory cytokines. EAE WT and EAE B 2 -/mice showed increased TNFα and IFNγ in brain tissue, when compared to the control group ( Figure 4D, E). However, no statistical difference was found in the cerebral cytokines levels between WT EAE and B 2 -/-EAE mice.

Discussion
The kallikrein-kinin system is one of the first inflammatory pathways activated after tissue damage. Particularly because of its ability to increase vascular permeability, the kallikrein-kinin system has been investigated for its ability to promote brain edema and secondary brain damage in various models of central nervous system injuries, for example; bacterial meningitis [28], traumatic brain and spinal cord injury [29][30][31][32], and global cerebral ischemia [4]. Although, kinins are known to be released and have several effects in the CNS, their cerebral effects in EAE pathogenesis remain unclear.
It is known that pretreatment with B2 receptor antagonist markedly inhibits inflammatory responses in lungs and intestine [15,33] by suppressing leukocyte recruitment and activation in acute models of inflammation [14,34,35]. In addition, treatment with a B2 receptor antagonist decreases CD44, CD54, CD11a and CD11b expression in various cell types after arthritis induction in Lewis rats [36].
This study was designed to provide further insights into the molecular mechanisms of proinflammatory cell trafficking into the CNS in a murine model of EAE. As kinin receptors appear to mediate leukocyte-endothelium interaction induced by certain inflammatory stimuli [4,13], our aim was to determine the putative role of kallikreinkinin system in the cerebral inflammatory response, via the kinin B2 receptor, after EAE development. For this, we used wild-type (WT) and kinin B2 receptor knockout (B 2 -/-) mice subjected to a MOG 35-55 -induced EAE model of multiple sclerosis.
The MOG peptide can induce typical EAE disease in C57BL/6 mice and in other strains. MOG, which represents only ~0.05% of myelin proteins, elicits a major antibody response that has been correlated with disease severity and demyelination in both human and animal models of MS [37,38]. There is some evidence for activation of the kallikrein-kinin system during inflammation in this model [39]. In our hands, mice that lack the kinin B 2 receptor and are subjected to EAE had a statistically significant reduction in neurological impairment at the peak of disease (day 14) and during the final plateau phase of disease, when compared with the WT EAE group. Our results also reveal lesser degrees of weight loss in EAE B 2 -/ mice when compared to WT EAE animals. These findings are consistent with a previous study that showed pro- Figure 3 Leukocyte-endothelial interactions in pial vasculature. Intravital microscopy was used to assess leukocytes rolling (A) and adhesion (B) on day 14 post-immunization. The analysis was performed in 4-5 vessels per animal (n = 6 per group). Results are expressed as mean ± SEM. ***P < 0.001 when compared to control; ### P < 0.001 when compared to EAE WT mice.  [40]. However, leukocyte recruitment was not investigated in this study. On the other hand, our findings of improvement of neurological clinical score in B 2 -/mice associated with impaired leukocyte recruitment parameters are in contrast to the findings of Xia et al. [41], which provide evidence for a protective role of the kinin B 2 receptor against ischemic stroke. In the latter study, the authors also found increased neutrophil accumulation in infarcted brain areas in B 2 -/mice. Recently these results have been consistently contested, leading to the conclusion that the deficiency of bradykinin receptor B2 is not detrimental in experimental stroke [42], and may be beneficial in other pathological conditions. EAE pathogenesis requires the infiltration of leukocytes into brain parenchyma. In a previous study undertaken by our group, we showed that there are increased leukocyteendothelial cell interactions (rolling and adhesion) in brains of EAE mice, as assessed by cerebral intravital microscopy [18]. In the present series of experiments, leukocyte adherence, but not rolling, was suppressed in B 2 -/mice submitted to the EAE protocol.

Leukocyte-endothelial interactions in pial vasculature
The latter findings were corroborated by histopathological examination of brain sections, which showed inhibition of mononuclear cell influx and inflammatory lesions on B 2 -/mice after EAE induction. In addition, histopathological analysis of spinal cord for EAE WT mice showed a marked inflammatory response with intense vacuolization in white matter, contrasting with very discrete infiltrates and degenerative changes in B 2 -/mice after EAE induction. Thus, the present study clearly suggests an important role for B 2 in mediating leukocyte adherence to vessels in brain, and extensively in spinal cord, as suggested by histology of both sites in the same animal.
These suggestions draw support from described patterns of kinin receptor distribution in the CNS. High-density kinin binding sites have been identified in the CNS, mainly in cerebral blood vessels [2]. Previous studies have demonstrated the presence of B 1 receptor in the brain and spinal cord in different species [43]. In addition, B 2 receptors have been localized in experimental brain tumors [44]. Chen et al have also shown that the B 2 receptor is widely expressed within rat brain [45]. In contrast to available knowledge on bradykinin B 2 receptors in brain, the distribution of these receoptors in spinal cord and the potential functional roles in spinal cord remain unclear. RT-PCR studies reveal the presence of B 1 and B 2 receptor mRNA in neurons of dorsal root ganglia in mice [46]. Murone et al. have demonstrated the distribution of B 2 receptors in the brain and spinal cord of guinea pig and sheep by autoradiography [47,48]. Further studies using intravital microscopy of spinal cord vessels are necessary in order to define functional roles of these receptors in pathological conditions. Activation of kinin receptors may underlie production of chemokines in several models of inflammation, including response to the cytokine IL-1β in mesenteric venules [49], inflammatory pain [50,51], and allergic rhinitis [21]. Considering previous data, it may be possible that kinin receptors could be regulating the expression of chemokines and, consequently, leukocyte trafficking after EAE induction. Our previous studies showed that the chemokines CCL2 and CCL5, but not CCL3, are involved in the adherence, but not rolling, of leukocytes in the microvasculature of EAE mice [18]. In this study we demonstrate that CCL5 expression is greatly suppressed in EAE B 2 -/mice, when compared to EAE WT. These findings could partially explain the inhibition of leukocyte adherence observed in B 2 -/mice, as a probable consequence of decreased levels of CCL5.
The chemokine CCL2 and its receptors CCR2 are thought to play an important role in the pathogenesis of EAE in several conditions. For example, both CCL2 and CCR2 are expressed in brains of patients with MS [52,53] and deletion of CCR2 leads to an almost complete inhibition of MOG 35-55 -induced EAE in mice [16]. Blocking of the CCL2-CCR2 axis with neutralizing antibodies limits the development of subsequent relapses [54]. Our previous studies have also shown a role for CCL2 in leukocyte adherence during murine EAE [18]. In the present experiments, CCL2 levels were lower in B 2 -/mice than in WT mice after EAE induction. Previous studies have shown that CCL2 may be critical not only for leukocyte recruitment but also for the activation of T cells during inflammatory and immune responses [53,55]. Thus, it is possible that the inhibition of CCL2 production observed in B 2 -/mice would lead to lesser activation of infiltrated leucocytes and, hence, stabilization of the severity of clinical signs.
There are many studies supporting the clinical involvement of TNF-α in EAE. Elevated expression of TNF-α can be found in the CNS during acute episodes of disease, and blockage of TNF-α with neutralizing antibodies and soluble receptors will ameliorate signs of EAE [56,57]. In order to evaluate the role of the B 2 receptor in cerebral TNF-α expression after EAE induction, brain tissue extracts were obtained from control, WT EAE and EAE B 2 -/mice. We found a significant increase in TNF-α levels at day 14 (peak of disease) in both WT and B 2 -/compared to control mice. Absence of B 2 receptor did not modulate TNF-α expression after EAE induction. These results are consistent with those of Cunha et al. [58] who demonstrated that B 2 kinin receptor antagonist, at a dose that inhibits carra-geenin-induced hypernociception, does not inhibit release of TNF-α [54]. Direct, bradykinin-independent, release of cytokines was also suggested in rats after administration of large doses of LPS [59]. B 2 is partially necessary for B 1 receptor induction as supported by the consistent finding of B 2 participation in B 1 mRNA and protein induction in several models of inflammation [60]. The expressed B 1 is relevant to the control of CCL5 production and to ensuing leukocyte adherence and tissue inflammation. In addition to these B 1 -dependent effects, B 2 receptor activation is necessary for the production of CCL2 in brains of EAE mice. Previous studies using rodent models of traumatic brain injury have corroborated the finding that B 2 receptor is present and involved in cerebral alterations [61,62]. Our study clearly demonstrates that blockade of B 2 receptors is beneficial in EAE mice in reducing inflammatory events such as leukocyte adhesion and activation. We should note, however, that various studies have demonstrated an important role for adhesion molecules in both EAE and MS pathogenesis [63][64][65][66] and, at this time, we can not yet exclude the possibility that there is altered expression of adhesion molecules such as ICAM-1 and VCAM-1 on brain endothelial cells of B 2 deficient animals.

Conclusion
Our study proposes an important and previously unappreciated involvement of the kallikrein-kinin system in the pathogenesis of EAE. In summary, our results clearly show a definite role for B 2 receptors in mediating leukocyte adherence, chemokine production and clinical disease outcome. Altogether, our data indicate that blockade of kinin receptors, especially B 2 , may represent an additional and novel therapeutic strategy for the treatment of MS.